CF Benchmarks
CF benchmarks logo

Nov 18, 2024

Suspension of Bitstamp as a Constituent Exchange for CME CF Cryptocurrency Pricing Products Family indices

The Administrator announces the suspension of Bitstamp as a CME CF Constituent Exchange for certain CME CF Cryptocurrency Pricing Products Family indices, from November 25th, 2024.

The indices are listed below.

  • CME CF Chiliz-Dollar Reference Rate (CHZUSD_RR)
  • CME CF Chiliz-Dollar Real Time Index (CHZUSD_RTI)
  • CME CF Curve-Dollar Reference Rate (CRVUSD_RR)
  • CME CF Curve-Dollar Real Time Index (CRVUSD_RTI)
  • CME CF Synthetix-Dollar Reference Rate (SNXUSD_RR)
  • CME CF Synthetix-Dollar Real Time Index (SNXUSD_RTI)

Rationale

The Administrator monitors Constituent Exchange trading volumes on an ongoing basis against the CME CF Constituent Exchanges Criteria in order to assess each venue's continuing eligibility to remain a Constituent Exchange. The Administrator has concluded that Bitstamp no longer meets the minimum spot trading volume requirements on a consistent basis. Accordingly, Bitstamp will be suspended as a Constituent Exchange for the benchmarks listed above. This suspension is indefinite.

Implementation Date

Bitstamp will be suspended as a Constituent Exchange from the benchmarks listed above at approximately 11:00 London Time, on November 25th, 2024. The suspension process has been overseen by the CME CF Cryptocurrency Pricing Products Oversight Committee.

Questions or queries regarding the suspension should be directed to [email protected].

Any complaints regarding the suspension can be made confidentially by writing to [email protected]


The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell any of the underlying instruments cited including but not limited to cryptoassets, financial instruments or any instruments that reference any index provided by CF Benchmarks Ltd. This communication is not intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. Please contact your financial adviser or professional before making an investment decision.


Note: Some of the underlying instruments cited within this material may be restricted to certain customer categories in certain jurisdictions.